Analysts Set Expectations for Supernus Pharmaceuticals, Inc.’s Q4 2017 Earnings (SUPN)
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Investment analysts at SunTrust Banks dropped their Q4 2017 EPS estimates for shares of Supernus Pharmaceuticals in a research note issued to investors on Thursday. SunTrust Banks analyst J. Boris now expects that the specialty pharmaceutical company will earn $0.26 per share for the quarter, down from their previous estimate of $0.27. SunTrust Banks also issued estimates for Supernus Pharmaceuticals’ FY2019 earnings at $3.17 EPS.
Several other brokerages also recently weighed in on SUPN. Piper Jaffray Companies raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $30.00 to $44.00 in a report on Thursday, June 1st. Jefferies Group LLC raised their price target on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, May 31st. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Thursday, May 11th. Cowen and Company raised their price target on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Finally, Zacks Investment Research downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $48.43.
COPYRIGHT VIOLATION NOTICE: “Analysts Set Expectations for Supernus Pharmaceuticals, Inc.’s Q4 2017 Earnings (SUPN)” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/14/analysts-set-expectations-for-supernus-pharmaceuticals-inc-s-q4-2017-earnings-supn.html.
Supernus Pharmaceuticals (NASDAQ SUPN) opened at 41.40 on Monday. Supernus Pharmaceuticals has a 1-year low of $17.25 and a 1-year high of $44.95. The firm’s 50-day moving average is $42.47 and its 200 day moving average is $34.12. The company has a market cap of $2.10 billion, a PE ratio of 20.89 and a beta of 1.31.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%.
Several large investors have recently added to or reduced their stakes in the company. Juncture Wealth Strategies LLC increased its stake in Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock worth $1,611,000 after buying an additional 433 shares during the period. Virginia Retirement Systems ET AL increased its stake in Supernus Pharmaceuticals by 17.1% in the first quarter. Virginia Retirement Systems ET AL now owns 71,800 shares of the specialty pharmaceutical company’s stock worth $2,247,000 after buying an additional 10,500 shares during the period. Turner Investments LLC purchased a new stake in Supernus Pharmaceuticals during the first quarter worth approximately $219,000. Sheets Smith Wealth Management purchased a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $378,000. Finally, Bank of America Corp DE increased its stake in Supernus Pharmaceuticals by 10.7% in the first quarter. Bank of America Corp DE now owns 362,952 shares of the specialty pharmaceutical company’s stock worth $11,361,000 after buying an additional 35,069 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.
In related news, VP Padmanabh P. Bhatt sold 3,735 shares of Supernus Pharmaceuticals stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the sale, the vice president now owns 21,209 shares of the company’s stock, valued at $952,284.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 2,556 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $44.90, for a total value of $114,764.40. Following the sale, the vice president now directly owns 24,944 shares of the company’s stock, valued at approximately $1,119,985.60. The disclosure for this sale can be found here. Insiders have sold 24,291 shares of company stock valued at $962,766 in the last ninety days. Corporate insiders own 6.70% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.